Dimebon Dimebolin Information Availability » Placebo Group

Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)

admin — Fri, 11 Jun 2010 05:12:37 +0000

Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion. The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday.

The company did note that a separate Phase 3 safety study demonstrated Dimebon’s tolerability when used alone or in combination with approved Alzheimer’s Disease medicines. Just one more problem… if it doesn’t work it doesn’t matter how tolerable it is. In some cases the placebo group even did better on the sugar pill, which is perhaps the worst endorsement a company can get.

http://www.dimebonalzheimers.com/

Drug May Ease Cognitive Effects of Huntington's

admin — Thu, 08 Apr 2010 02:50:34 +0000

Small study reports improvement in thinking skills.

An experimental drug may improve thinking, learning and memory skills in people with Huntington’s disease, an inherited neurodegenerative disorder, new research says.

Huntington’s affects movement, behavior and cognitive abilities, and people with the disease usually die within 10 to 30 years of its onset. Cognitive problems begin early in the disease and increase as Huntington’s progresses, leading to the inability to work or perform normal daily activities.

Currently, the only approved therapy for Huntington’s is tetrabenazine, which treats movement problems but does not prevent cognitive decline or change the course of the disease.

In the new study, researchers assessed the safety and tolerability of a new drug with the proposed generic name latrepirdine, in people with mild to moderate Huntington’s disease. The drug stabilizes and improves the function of mitochondria, parts of cells that help convert food into energy. Previous research has suggested that mitochondria abnormalities could play a role in Huntington’s.

For 90 days, 46 people took 20 milligrams of latrepirdine three times a day, and 45 others took a placebo. The researchers said the drug was well-tolerated (87 percent of people taking latrepirdine completed the study, compared with 82 percent of the others), and the rates of adverse events were 70 percent in the treatment group, 80 percent in the placebo group.

The researchers also found that average scores on scales rating overall cognitive function improved in the treatment group and remained the same in the placebo group.

“Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well-tolerated for 90 days in patients with Huntington’s disease and may have a beneficial effect on cognition,” wrote Dr. Karl Kieburtz, of the School of Medicine and Dentistry at the University of Rochester in New York, and his colleagues.

“Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington’s disease,” they added.

The study is published in the February issue of Archives of Neurology.

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

Side Effects Dosage of Razadyne fro Alzheimer's

admin — Mon, 16 Feb 2009 12:58:18 +0000

Advantages of Razadyne ( galantamine) include that it may not as much disturb sleep and the sleep process in Alzheimer’s patients as the other mainstay medication of treatment of Alzheimer’s Aricept.

Common side effects of Razadyne include possible nausea , vomiting ,diarrhea ,fainting , loss of appetite and weight loss.? Most of these are mild and tend to subside as the body learns to adjust to the medication over time.

In M.C.I. trials Razadyne , thirteen ( 13) Razadyne recipients died, compared to only a single ( one) death among placebo patients – a finding that it seems of not many doctors are aware of.? Because more deaths occurred in the Razadyne group , than in the placebo group, doctors cannot rule out that the deaths were somehow related or due to Razadyne therapy.

Razadyne therapy can be initiated for patients with mild or moderate Alzheimer’s disease.

Dosage:? Razadyne? is supplied in both regular and extended release forms. Razadyne ER ( or SR designation slow- release formulation), can be taken once a day whereas Razadyne immediate release formulations are taken on a twice a da regime.? The two different formulations of Razadyne – immediate release and slow extended or sustained release formulations should not be taken together at the same time.? Its either one or the other since the active medication ingredient is the same.

The effective dose of Razadyne Extended Release (ER)? as well as immediate release ( regular) Razadyne? is stated to be in the ranges of 16 to 24 milligrams a day.? Doctors usually recommend starting with a lower initial dose of 8 milligrams a day and then increasing it to the lower maintenance dosage of 16 mg over a time span period of four ( 4) weeks. Then up according to the specific patients requirements and needs over a time span the dosage can be increased to upper stated limits of the drug.? Often patients can tolerate medications at higher levels if first started on a much lower initial dose and the dosage increased slowly over time.? The maxim is start lower and increase dosage slowly over time.

To reduce side effects , in terms of sleep disturbances and insomnia it is especially recommended to take the medication in the morning time with the extended release ER / SR form , and the taking of the second dose of the immediate release form somewhat earlier during the 24 clock of the daytime rather than later.

Dimebon Alzheimer?s Disease

http://www.psychiatry.co.il/

????????-?”? ???? ?? ???, ????? ?????????,????????? ??????

http://www.dimebonalzheimers.com